{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:44:05Z","timestamp":1790534645993,"version":"4.1.0"},"reference-count":12,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2022,8,1]]},"DOI":"10.1001\/jamaoncol.2022.1641","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T15:01:11Z","timestamp":1655391671000},"page":"1128","source":"Crossref","is-referenced-by-count":58,"title":["Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer"],"prefix":"10.1001","volume":"8","author":[{"given":"Neal D.","family":"Shore","sequence":"first","affiliation":[{"name":"Carolina Urologic Research Center, Myrtle Beach, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Renzulli","sequence":"additional","affiliation":[{"name":"Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil E.","family":"Fleshner","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney M. P.","family":"Hollowell","sequence":"additional","affiliation":[{"name":"Cook County Health, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Vourganti","sequence":"additional","affiliation":[{"name":"Rush University Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Silberstein","sequence":"additional","affiliation":[{"name":"Memorial Healthcare System, Hollywood, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizwan","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc, Northbrook, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hairston","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc, Northbrook, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Elsouda","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc, Northbrook, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Russell","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Cooperberg","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Tomlins","sequence":"additional","affiliation":[{"name":"Departments of Pathology and Urology, Rogel Cancer Center, University of Michigan Medical School, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"coi220020r1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.v70.1","article-title":"Cancer statistics, 2020.","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"coi220020r4","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.juro.2014.02.005","article-title":"Targeted prostate biopsy in select men for active surveillance: do the Epstein criteria still apply?","volume":"192","author":"Hu","year":"2014","journal-title":"J Urol"},{"issue":"9821","key":"coi220020r5","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S0140-6736(11)61619-X","article-title":"Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.","volume":"379","author":"Fleshner","year":"2012","journal-title":"Lancet"},{"issue":"9","key":"coi220020r6","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1158\/1078-0432.CCR-16-1357","article-title":"Neoadjuvant enzalutamide prior to prostatectomy.","volume":"23","author":"Montgomery","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"5","key":"coi220020r7","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.eururo.2015.01.027","article-title":"Long-term efficacy and safety of enzalutamide monotherapy in hormone-naive prostate cancer: 1- and 2-year open-label follow-up results.","volume":"68","author":"Tombal","year":"2015","journal-title":"Eur Urol"},{"issue":"13","key":"coi220020r8","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy.","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"coi220020r9","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy.","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"coi220020r10","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer.","volume":"378","author":"Hussain","year":"2018","journal-title":"N Engl J Med"},{"issue":"32","key":"coi220020r11","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer.","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi220020r12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer.","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"coi220020r2","unstructured":"National Cancer Institute. Stage distribution of SEER incidence cases, 2009-2018. Accessed June 1, 2021. https:\/\/seer.cancer.gov\/explorer\/application.html?site=66&data_type=1&graph_type=4&compareBy=race&chk_race_1=1&chk_race_5=5&chk_race_4=4&chk_race_3=3&chk_race_6=6&chk_race_8=8&chk_race_2=2&hdn_sex=2&age_range=1&advopt_precision=1&advopt_display=2#tableWrap."},{"key":"coi220020r3","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer version 2.2021. Accessed April 1, 2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate_blocks.pdf."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2793567\/jamaoncology_shore_2022_oi_220020_1660581536.26699.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T15:02:05Z","timestamp":1660921325000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2793567"}},"subtitle":["The ENACT Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2022.1641","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,1]]}}}